ARBUTUS BIOPHARMA CORP
NASDAQ: ABUS (Arbutus Biopharma Corporation)
最近更新时间: 3小时之前4.85
-0.03 (-0.61%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Arbutus Biopharma Corporation | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | -3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.75 |
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 21.89% |
| 机构持股比例 | 59.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Two Seas Capital Lp | 30 Jun 2026 | 19,095,583 |
| Whitefort Capital Management, Lp | 30 Jun 2026 | 15,794,261 |
| Blackbarn Capital Partners Lp | 30 Jun 2026 | 2,500,000 |
| Woodline Partners Lp | 30 Jun 2026 | 2,281,856 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ANDROSKI LINDSAY | - | 5.01 | -82,527 | -413,460 |
| BEARDSLEY ROBERT A | - | 5.01 | -99,057 | -496,276 |
| NGUYEN TUAN | - | 5.01 | -206,637 | -1,035,251 |
| SAWHNEY ROGER | - | 5.01 | -100,508 | -503,545 |
| 累积净数量 | -488,729 | |||
| 累积净值 ($) | -2,448,532 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 5.01 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BEARDSLEY ROBERT A | 董事 | 18 Sep 2026 | 处理 (-) | 99,057 | 5.01 | 496,276 |
| BEARDSLEY ROBERT A | 董事 | 18 Sep 2026 | 执行期权 | 131,333 | - | - |
| SAWHNEY ROGER | 董事 | 18 Sep 2026 | 处理 (-) | 100,508 | 5.01 | 503,545 |
| SAWHNEY ROGER | 董事 | 18 Sep 2026 | 执行期权 | 131,333 | - | - |
| NGUYEN TUAN | 职员 | 18 Sep 2026 | 处理 (-) | 206,637 | 5.01 | 1,035,251 |
| NGUYEN TUAN | 职员 | 18 Sep 2026 | 执行期权 | 293,100 | - | - |
| ANDROSKI LINDSAY | 职员 | 18 Sep 2026 | 处理 (-) | 82,527 | 5.01 | 413,460 |
| ANDROSKI LINDSAY | 职员 | 18 Sep 2026 | 执行期权 | 126,864 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合